CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Open Access
- 1 September 1998
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 102 (5), 1115-1123
- https://doi.org/10.1046/j.1365-2141.1998.00930.x
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myelomaBone Marrow Transplantation, 1998
- Plateau phase in multiple myeloma: an analysis of long‐term follow‐up of 432 patientsBritish Journal of Haematology, 1996
- Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantationThe International Journal of Cell Cloning, 1996
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP)European Journal of Cancer and Clinical Oncology, 1986
- REAPPRAISAL OF PLATEAU PHASE IN MYELOMAThe Lancet, 1980
- Smoldering Multiple MyelomaNew England Journal of Medicine, 1980
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979